Sangamo Therapeutics, Inc. (SGMO)
Sangamo Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Sangamo Therapeutics, Inc. (SGMO) is a Biotechnology company based in US with a market capitalization of $30.7M. Revenue declined 31.6% year-over-year and free cash flow was negative at -$97.3M. This page tracks SGMO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 183 employees · IPO Apr 6, 2000
Valuation
Valuation & price
$0.14as of May 17, 2026· -81.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$30.7M
Market cap
-31.6%
Revenue growth (YoY)
80.8%
Gross margin
-$97.3M
Free cash flow (USD)
$5.8M
Net debt
38.9%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-0.07)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 1, 2026Filing
Bankruptcy Filing
- 8-K eventJun 23, 2026Filing
Asset Purchase Agreement
- 8-K eventJun 23, 2026Filing
Bankruptcy Filing
- 8-K eventMay 14, 2026Filing
Business Highlights and Financial Results
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- Annual reportApr 30, 2026Filing
10-K Filed
- 8-K eventApr 29, 2026Filing
Delisting Notice
- Insider sellApr 23, 2026Filing
Insider Sell $89KDubois-Stringfellow Nathalie · SVP-CHIEF DEVELOPMENT OFFICER · $89.2K
- Insider sellApr 23, 2026Filing
Insider Sell $18KDavis Gregory D · Head of Research & Technology · $17.7K
Questions
Frequently asked questions
What is Sangamo Therapeutics, Inc.'s market cap?
Sangamo Therapeutics, Inc. (SGMO) has a market capitalization of $30.7M.
What is SGMO's P/E ratio?
A meaningful P/E ratio is not available for SGMO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
When did Sangamo Therapeutics, Inc. last report earnings?
SGMO last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying SGMO stock?
SEC Form 4 filings show no open-market insider buys at Sangamo Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.